When Roger was diagnosed with amyotrophic lateral sclerosis (ALS), a debilitating neurodegenerative disorder, he decided to participate in a clinical trial. Timothy Miller, MD, PhD, ALS Center Director at Washington University School of Medicine in St. Louis, describes the SOD1 clinical trial in the context of Roger's story. Data from this study will be used to better understand ALS and discover markers that may inform how treatments work. Dr Miller emphasizes the importance of clinical trial participation for helping other patients with ALS.